Drug Profile
Evenamide - Newron Pharmaceuticals
Alternative Names: NW-3509; NW-3509ALatest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Newron Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; NAV1.7 voltage gated sodium channel expression inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; NAV1.8 voltage gated sodium channel expression inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 5-HT2 receptor agonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- Phase II/III Psychiatric disorders
Most Recent Events
- 04 Jan 2024 Pooled efficacy and adverse event data from phase III 014/015 trial in Schizophrenia released by Newron Pharmaceuticals
- 29 Dec 2023 Newron Pharmaceuticals completes enrolment in a phase II/III trial in Schizophrenia (Adjunctive treatment) in Latvia, Estonia, Poland, Hungary, Spain, Romania, Czech Republic, Italy, Germany (PO) (EudraCT2020-006062-36)
- 09 Oct 2023 Efficacy and adverse events data from a phase III 014/015 trial in Schizophrenia released by Newron Pharmaceuticals